RxDoctor Payments Data

Oscar Escobar, PA

Physician Assistant · Pacoima, CANPI 1477670750

Payments from drug & device makers

$2,704in general payments, 2019–2025

Across 129 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$821
  • AbbVie$551
  • Bayer$300
  • Boehringer Ingelheim$149
  • Novo Nordisk$127
  • GSK$126
  • plus $630 from 14 others

What the payments were for

  • Food & beverage$2,704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,704 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$31,562
Medicare patients
49
Services billed
392

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin67$86,277
OzempicSemaglutide91$85,430
LinzessLinaclotide34$38,167
JanuviaSitagliptin Phosphate23$27,741
EliquisApixaban19$27,109
Janumet XrSitagliptin Phos/Metformin Hcl23$18,999
TradjentaLinagliptin12$16,442
SynjardyEmpagliflozin/Metformin Hcl18$14,717
Breo ElliptaFluticasone/Vilanterol32$11,885
SeglurometErtugliflozin/Metformin12$8,820
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$7,923
Tresiba Flextouch U-200Insulin Degludec16$7,295
Icosapent Ethyl18$5,703
Humalog Kwikpen U-100Insulin Lispro12$5,219
LumiganBimatoprost11$4,744

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Synjardy$149$117,43597 claims
Novo NordiskOzempic$127$85,43091 claims
MerckJanuvia, Janumet Xr, Segluromet$105$55,56058 claims
AbbVieLinzess, Lumigan$551$42,91045 claims
PfizerEliquis$107$27,10919 claims
GSKBreo Ellipta$126$11,88532 claims
Lilly USA, LLCHumulin 70-30$821$1,98813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Pacoima

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →